

Express Mail Label No.: EV 317 172 762 US
Date: August 1, 2003

Attorney Docket No. VPI/00-130-03 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: David Bebbginton, et al.
CONTINUATION OF: 10/025,164 Examiner: Sudhaker B. Patel
FILING DATE: HEREWITH GROUP ART UNIT: 1624
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

August 1, 2003
Cambridge, Massachusetts 02139

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make of record the documents listed on the Modified Form PTO-1449 (submitted herewith in duplicate). Copies of the listed documents are submitted herewith.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. § 1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified application.


Accordingly, no fee or certification is required under 37 C.F.R. § 1.97.

Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. Applicants also request that a copy of the enclosed form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

APPLICANTS: David Bebbington, et al.

The Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment to Deposit Account No. 50-0725, Reference No. VPI/00-130-03 CON US.

Respectfully submitted,



Andrea L.C. Robidoux, Reg. No. 47,902
Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444- 6731
Fax: (617) 444-6483

modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	David Bebbington
	Group Art Unit	Sudhaker B. Patel
	Examiner Name	1624
	Attorney Docket Number	VPI/00-130-03 CON US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	US 2001/0018436	30-Aug-2001	Tularik Inc.			
	A2*	2002/0065270	05/30/2002	Bristol-Myers Squibb Company			
	A3*	USSN 10/025,164		Vertex Pharmaceuticals Incorporated			19-Dec-2001

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*		WO 02/18346	Pfizer Products, Inc. .	07-Mar-2002		
	B2*		WO 00/39101	Astrazeneca UK Limited	06-Jul-2000		
	B3*		WO 00/21955	Zeneca Limited	20-Apr-2000		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/025,164, filed December 19, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.